C2n Diagnostics LLC

Tim West

Andrew Corey Paoletti

Timothy David Jones

Francis J Carr

Diljeet Singh Athwal

Francis Joseph Carr

Robert George Edward Holgate

Andrew C Paoletti

Robert George Holgate

Timothy D Jones

Diljeet S Athwal

The invention generally relates to methods for the diagnosis and treatment of neurological and neurodegenerative diseases, disorders, and associated processes. Specifically, the present invention is directed toward methods to determine prognosis, diagnosis or efficacy of a therapeutic regimen by using a detectable label to measure levels of alpha-synuclein.

Methods for the diagnosis and treatment of neurological and neurodegenerative diseases, disorders and associated processes

The present invention provides methods for measuring the absolute concentration of a biomolecule of interest in a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention.

Methods for measuring concentrations of biomolecules

Provided herein is an isolated antibody or antigen-binding fragment that specifically binds tau, the antibody or fragment comprising a heavy chain variable (VH) region and a light chain variable (VL) region having amino acid sequences set forth herein. Also provided are methods of preventing or treating a tauopathy in a subject, comprising administering to a human in need of therapy for a tauopathy with one or more antibodies or fragments as described herein, wherein the antibodies or antigen-binding fragment are administered under conditions and in an amount effective to prevent or treat the tauopathy.

Humanized anti-tau antibodies

Growing community of inventors

Saint Louis, MO, United States of America

Tim West